Amgen raises profit outlook after posting a strong second quarter
Amgen Inc. said strong sales of its rheumatoid arthritis drug Enbrel, osteoporosis drug Prolia, and other treatments, lifted its second-quarter profits and prompted the company to raise its financial forecast for the year.
Thousand Oaks-based Amgen(Nasdaq: AMGN) said its earnings rose to $1.65 billion, or $2.15 per share, from $1.55 billion, or $2.01 per share, a year ago. Income excluding one-time charges was $1.98 billion, or $2.57 per share, 14 cents higher than a prediction by Factset analysts.
Revenue…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Source Type: news
More News: Arthritis | Enbrel | Health | Health Management | Hospital Management | Hospitals | Orthopaedics | Osteoporosis | Profits and Losses | Rheumatoid Arthritis | Rheumatology